ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Angioedema,Angioedemas,Angioedema and urticaria,Skin,N
1,2,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
1,3,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
2,1,Alcohol intolerance,Food malabsorption and intolerance syndromes (excl sugar intolerance),Food intolerance syndromes,Metab,N
3,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
4,1,Parkinson's disease,Parkinson's disease and parkinsonism,Movement disorders (incl parkinsonism),Nerv,N
5,1,Injection site atrophy,Injection site reactions,Administration site reactions,Genrl,N
6,1,Injection site atrophy,Injection site reactions,Administration site reactions,Genrl,N
7,1,Cystitis,Urinary tract infections,Infections - pathogen unspecified,Infec,N
7,2,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
8,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
9,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
10,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
11,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
11,2,Diabetic coma,Coma states,Neurological disorders NEC,Nerv,N
12,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
13,1,Anaphylactoid reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
14,1,Injection site atrophy,Injection site reactions,Administration site reactions,Genrl,N
14,2,Lipodystrophy acquired,Lipodystrophies,Skin and subcutaneous tissue disorders NEC,Skin,N
15,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
16,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
17,1,Injection site inflammation,Injection site reactions,Administration site reactions,Genrl,N
18,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
19,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
20,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
20,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
21,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
21,2,Product administration error,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
22,1,Skin test positive,Immunology skin tests NEC,Immunology and allergy investigations,Inv,N
23,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
24,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
24,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
24,3,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
25,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
26,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
27,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
28,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
28,2,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
29,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
29,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
29,3,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
30,1,Diabetic neuropathy,Chronic polyneuropathies,Peripheral neuropathies,Nerv,N
30,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
30,3,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
30,4,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
31,1,Acute pulmonary oedema,Pulmonary oedemas,Lower respiratory tract disorders (excl obstruction and infection),Resp,Y
31,2,Hypoxia,Conditions associated with abnormal gas exchange,Respiratory disorders NEC,Resp,N
31,3,Left ventricular failure,Left ventricular failures,Heart failures,Card,N
31,4,Pulmonary hypertension,Pulmonary hypertensions,Pulmonary vascular disorders,Resp,N
31,5,Right ventricular failure,Right ventricular failures,Heart failures,Card,N
